

FDA's Center for Veterinary Medicine Strategic Goals for FY 2026 - 2028

While CVM is the smallest center within the U.S. Food and Drug Administration, the commodities CVM regulates cover a broad spectrum that ranges from animal drugs to animal devices, and animal food to animal biotechnology. The Center's role is to ensure products under its regulatory jurisdiction are safe for all animals, including pets, honeybees, aquaculture, livestock animals, and zoo animals. CVM's vital and varied areas of focus showcase exceptional staff capable of meeting emerging health needs while aligning with Agency priorities.

CVM's core vision and mission

Vision: Excellence. Innovation. Leadership.

Mission: Protecting Human and Animal Health.

To guide CVM through a changing landscape and help prioritize initiatives, CVM's Center Executive Board has identified four goals for fiscal years (FY) 2026 – 2028.

- **Goal 1.** Promote Organizational Excellence
- **Goal 2.** Expedite cures and safe food products for animals
- **Goal 3.** Strengthen Human and Animal Health Protection Capabilities
- **Goal 4.** Enhance and Leverage Partnerships

These goals are intended to guide CVM's development and growth, balancing organizational needs with program enhancements to support its mission and vision through FY2028.

Goal 1. Promote Organizational Excellence

CVM's people, culture, and management systems are the engines that power our daily work. A high-performing, adaptable workforce and effective performance management are not optional. By continuously refining our work culture and the processes that drive our results, CVM sustains its high standards in organizational excellence.

Objectives

1. Strengthen CVM's culture of adaptability, collaboration, and continuous learning.
2. Enhance performance measures across CVM to provide high impact results and accountability.
3. Adopt and contribute to the development of agency's data processes and technology infrastructure.

Goal 2. Expedite Cures and Safe Food Products for Animals

Unmet needs demand regulatory flexibility, which in turn, fuels innovation. CVM is creating new, modernized regulatory pathways for animal food and drugs, reducing regulatory burden and duplicative testing, and accelerating access to needed therapies and novel food ingredients, feeding a positive cycle of product development and approval.

Objectives

1. Address unmet high-priority, stakeholder needs.
2. Align regulatory requirements with a modern landscape.
3. Support new product technology and novel product development.

Goal 3. Strengthen Human and Animal Health Protection Capabilities

Protecting human and animal health requires both readiness and foresight. CVM is building operational capacity by integrating crisis response, proactive programs, and robust infrastructure, including data systems, surveillance networks, and resilient supply chains, to meet both immediate threats and long-term challenges.

Objectives

1. Prepare and respond to emergent health threats.
2. Implement priority, long-term initiatives for protecting human and animal health.
3. Strengthen supply chains, enhance surveillance and data collection.

Goal 4. Enhance and Leverage Partnerships

Complex regulatory challenges require collaboration. CVM will actively cultivate partnerships that engage with external perspectives, emerging technologies, and innovative approaches, keeping CVM adaptable and ahead of evolving risks across domestic and global landscapes.

Objectives

1. Increase harmonization and scientific collaboration with international regulatory partners to promote innovation, standardization, and the safety and efficacy of FDA-regulated products, while advancing U.S. competitiveness in the global market.
2. Build and enhance domestic coalitions with states, industry, academia, consumer and patient groups to leverage FDA resources for broader impact.
3. Strengthen cross-government coordination to improve public health outcomes for Americans.